@article{RantamaekiVesaAntilaetal.2011,
  author    = {Rantam{\"a}ki, Tomi and Vesa, Liisa and Antila, Hanna and Di Lieto, Antonio and Tammela, P{\"a}ivi and Schmitt, Angelika and Lesch, Klaus-Peter and Rios, Maribel and Castr{\´e}n, Eero},
  title     = {Antidepressant Drugs Transactivate TrkB Neurotrophin Receptors in the Adult Rodent Brain Independently of BDNF and Monoamine Transporter Blockade},
  series = {PLoS ONE},
  volume    = {6},
  journal   = {PLoS ONE},
  number    = {6},
  doi       = {10.1371/journal.pone.0020567},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-133746},
  pages     = {e20567},
  year      = {2011},
  abstract  = {Background: Antidepressant drugs (ADs) have been shown to activate BDNF (brain-derived neurotrophic factor) receptor TrkB in the rodent brain but the mechanism underlying this phenomenon remains unclear. ADs act as monoamine reuptake inhibitors and after prolonged treatments regulate brain bdnf mRNA levels indicating that monoamine-BDNF signaling regulate AD-induced TrkB activation in vivo. However, recent findings demonstrate that Trk receptors can be transactivated independently of their neurotrophin ligands. Methodology: In this study we examined the role of BDNF, TrkB kinase activity and monoamine reuptake in the AD-induced TrkB activation in vivo and in vitro by employing several transgenic mouse models, cultured neurons and TrkB-expressing cell lines. Principal Findings: Using a chemical-genetic TrkB(F616A) mutant and TrkB overexpressing mice, we demonstrate that ADs specifically activate both the maturely and immaturely glycosylated forms of TrkB receptors in the brain in a TrkB kinase dependent manner. However, the tricyclic AD imipramine readily induced the phosphorylation of TrkB receptors in conditional bdnf(-/-) knock-out mice (132.4+/-8.5\% of control; P = 0.01), indicating that BDNF is not required for the TrkB activation. Moreover, using serotonin transporter (SERT) deficient mice and chemical lesions of monoaminergic neurons we show that neither a functional SERT nor monoamines are required for the TrkB phosphorylation response induced by the serotonin selective reuptake inhibitors fluoxetine or citalopram, or norepinephrine selective reuptake inhibitor reboxetine. However, neither ADs nor monoamine transmitters activated TrkB in cultured neurons or cell lines expressing TrkB receptors, arguing that ADs do not directly bind to TrkB. Conclusions: The present findings suggest that ADs transactivate brain TrkB receptors independently of BDNF and monoamine reuptake blockade and emphasize the need of an intact tissue context for the ability of ADs to induce TrkB activity in brain.},
  language  = {en}
}
@article{WuPuAllenetal.2012,
  author    = {Wu, Lingdan and Pu, Jie and Allen, John J. B. and Pauli, Paul},
  title     = {Recognition of facial expressions in individuals with elevated levels of depressive symptoms: an eye-movement study},
  series = {Depression Research and Treatment},
  volume    = {2012},
  journal   = {Depression Research and Treatment},
  number    = {249030},
  doi       = {10.1155/2012/249030},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-123153},
  year      = {2012},
  abstract  = {Previous studies consistently reported abnormal recognition of facial expressions in depression. However, it is still not clear whether this abnormality is due to an enhanced or impaired ability to recognize facial expressions, and what underlying cognitive systems are involved. The present study aimed to examine how individuals with elevated levels of depressive symptoms differ from controls on facial expression recognition and to assess attention and information processing using eye tracking. Forty participants (18 with elevated depressive symptoms) were instructed to label facial expressions depicting one of seven emotions. Results showed that the high-depression group, in comparison with the low-depression group, recognized facial expressions faster and with comparable accuracy. Furthermore, the high-depression group demonstrated greater leftwards attention bias which has been argued to be an indicator of hyperactivation of right hemisphere during facial expression recognition.},
  language  = {en}
}
@article{VolkertZierhutSchieleetal.2014,
  author    = {Volkert, Julia and Zierhut, Kathrin C. and Schiele, Miriam A. and Wenzel, Martina and Kopf, Juliane and Kittel-Schneider, Sarah and Reif, Andreas},
  title     = {Predominant polarity in bipolar disorder and validation of the polarity index in a German sample},
  doi       = {10.1186/s12888-014-0322-8},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-111042},
  year      = {2014},
  abstract  = {Background: A large number of patients with bipolar disorder (BD) can be characterized by predominant polarity (PP), which has important implications for relapse prevention. Recently, Popovic et al. (EUR NEUROPSYCHOPHARM 22(5): 339-346, 2012) proposed the Polarity Index (PI) as a helpful tool in the maintenance treatment of BD. As a numeric expression, it reflects the efficacy of drugs used in treatment of BD. In the present retrospective study, we aimed to validate this Index in a large and well characterized German bipolar sample. Methods: We investigated 336 bipolar patients (BP) according to their PP and calculated the PI for each patient in order to prove if maintenance treatment differs according to their PP. Furthermore, we analysed whether PP is associated with demographic and clinical characteristics of BP. Results: In our sample, 63.9\% of patients fulfilled criteria of PP: 169 patients were classified as depressive predominant polarity (DPP), 46 patients as manic predominant polarity (MPP). The two groups differed significantly in their drug regime: Patients with DPP were more often medicated with lamotrigine and antidepressants, patients with MPP were more often treated with lithium, valproate, carbamazepine and first generation antipsychotics. However, patients with DPP and MPP did not differ significantly with respect to the PI, although they received evidence-based and guideline-driven treatment. Conclusion: The reason for this negative finding might well be that for several drugs, which were used frequently, no PI value is available. Nevertheless we suggest PP as an important concept in the planning of BD maintenance treatment.},
  language  = {en}
}